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Background: To evaluate the long-term outcome of bevacizumab therapy for neovascular age related macular
degeneration (NVAMD) in the setting of a clinic.
Methods: Consecutive group of NVAMD patients who were treated in a single 3rd referral center with bevacizumab
using a loading dosage of 3 monthly injections followed by variable dosing for at least 48 months were retrospectively
evaluated. Genotyping was performed for CFH (rs1061170), HTRA1 (rs1200638), and C3 (rs2230199). Main outcome
measures included functional and morphological treatment outcomes as well as their risk allele associations.
Results: Out of 128 patients who started bevacizumab treatment over 4 years before the study endpoint [mean (±SD):
60 ± 10.9 months], 75 eyes of 67 (52.3%) patients, were still followed. Mean best corrected visual acuity (BCVA)
(LogMAR ± SEM) improved from 0.66 ± 0.07 at baseline to 0.48 ± 0.05 (p = 0.012) at 1 year, but deteriorated from the
3rd year on and at the final exam reduced to 0.69 ± 0.07 (p = 0.6, compared with initial BCVA). Macular thickness
mirrored visual acuity (VA) changes showing initial thinning followed by thickening from the 3rd year on. Individuals
carrying the CFH risk -allele had a mean thickening (microns ± SEM) of 66.9 ± 70.4 versus a mean thinning of 76.8 ± 22
in non-carriers (p = 0.015).
Conclusions: Bevacizumab therapy for NVAMD using a flexible treatment algorithm in a “real life” clinical setting
initially obtained VA gain and thinning of the macula that were maintained for two years, but were lost later on.
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Long-termBackground
Multiple clinical trials have documented improved short-
and intermediate term visual acuity (VA) following appli-
cation of anti-vascular endothelial growth factor (VEGF)
therapy in neovascular age related macular degeneration
(NVAMD) [1-4]. Such visual gain was obtained for up to
two years using bevacizumab, ranibizumab or aflibercept
utilizing either fixed or pro re nata (PRN) regimens of in-
traocular injections [1,4,5].
Limited data is available on the long-term outcome of
VEGF blockade in NVAMD, and this data focuses on
ranibizumab [6-11]. It has been suggested that most of
the visual gain obtained during the first one to two years* Correspondence: chowers@hadassah.org.il
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unless otherwise stated.of treatment may be lost later on. The Open-Label
Extension Trial of Ranibizumab for Choroidal Neovascu-
larization Secondary to Age-Related Macular Degener-
ation (HORIZON) provides follow-up for two additional
years of PRN ranibizumab treatment among patients
who previously had completed two years within the
ANCHOR, MARINA, or FOCUS trials. The study re-
ported on 361 patients and showed that at four years fol-
lowing initiation of therapy the majority of visual gain
obtained in the first months of therapy was lost [9]. The
Seven-Year Outcomes in Ranibizumab-Treated Patients
in ANCHOR, MARINA, and HORIZON (SEVEN-UP)
study recently provided the longest currently available
follow-up of seven years after initiation of ranibizumab
treatment. Sixty-five patients out of the 357 patients ori-
ginally randomized to ranibizumab in the ANCHOR orThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pation in the HORIZON study were re-examined. A mean
loss of 8 letters compared with the initial VA was reported,
and vision loss appears to progress with time for some of
the eyes. Forty-six percent of the eyes that were re-
examined were still receiving anti-VEGF treatment [6].
The long-term safety of ranibizumab 0.5 mg in neo-
vascular age-related macular degeneration (SECURE)
study, which provided an additional 24 months of follow
up after completion of a 12-month treatment period of
two other (EXCITE and SUSTAIN) studies, also showed
that a visual acuity-guided regimen of ranibizumab ad-
ministration led to a best corrected visual acuity (BCVA)
reduction from study baseline [8].
In the clinic setting, Pushpoth et al. reported that 50%
of 110 NVAMD patients who were treated with ranibi-
zumab for NVAMD and followed for four years main-
tained visual acuity (VA) of at least 0.3 [11]. Rasmussen
and colleagues reported of stable VA of approximately
0.3 decimal in 192 NVAMD eyes treated with ranibizu-
mab for 4 years [10].
Advances in genetics over the last few years inspired
the idea that genetic testing-guided personalized medi-
cine may become a reality in ophthalmology. Single nu-
cleotide polymorphisms (SNPs) and rare variants in over
20 genes are currently known to be associated with the
risk for manifesting AMD [12-16]. Yet, conflicting infor-
mation was reported with respect to the existence of
pharmacogenetic interactions among these variants in
the context of anti-VEGF therapy [17-21], and long-term
data on this issue is lacking.
We aimed to assess the long-term outcome of bevaci-
zumab therapy for NVAMD in the “real life” setting of a
clinic (rather than a controlled study) and to evaluate for
potential pharmacogenetic interactions. To that end,
NVAMD patients who underwent continuous treatment
for at least 4 years were evaluated for final VA, anatom-
ical response, and potential interaction of outcomes with
genotyping for the major risk SNPs associated with
AMD.
Methods
A single center retrospective study was performed. All
NVAMD patients who presented between January 2006
to January 2008 to the retina clinic of the Hadassah
Medical Center and treated for at least 48 months with
either intravitreal bevacizumab alone or in combination
with ranibizumab injections were identified by computer
search of the clinic database. Institutional review board
approval was obtained.
Data recorded included demographics (age and gen-
der), ophthalmic findings including BCVA on an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart,
and choroidal neovascularization (CNV) characteristicsaccording to fluorescein angiogram (FA). Morphological
characteristics of the lesion before and during follow-up
were assessed using optical coherence tomography (OCT;
stratus OCT [Carl Zeiss Meditec, Inc. Dublin, CA] for all
case up to 2009 and Spectralis HRA-OCT [Heidelberg
Engineering, Heidelberg, Germany]) from 2009 and on.
Imaging scans were assessed and analyzes by a masked ob-
server. A Correction factor of 70 microns was added to
the Stratus OCT measurements to allow calculation along
with the Spectralis OCT driven values [22].
The treatment algorithm included three consecutive
monthly intravitreal injections of 1.25 mg bevacizumab,
followed by an OCT-guided individualized treatment
regimen for at least 48 months. Clinical examination
and OCT were performed following each injection. In
some cases, when treatment failure under bevacizumab
was detected, second line therapy with ranibizumab was
attempted. Need for retreatment and drug switch was
determined by the treating physician (IC, EA, EB, IH)
based on assessment of disease activity according to VA,
ophthalmoscopy, and OCT, as well as FA when required.
OCT guidelines used for retreatment included persist-
ence or recurrence of either intra-retinal, sub-retinal or
sub-retinal pigment epithelium fluid. These guidelines
were similar for all four physicians. New subretinal
hemorrhage was also mandated re-treatment. In case
where the visual acuity dropped but the OCT failed to
demonstrate fluid, fluorescein angiography was per-
formed and re-treatment was provided if active CNV
was demonstrated. While no specific lower visual acuity
threshold for treatment was determined, treatment was
withheld in eyes with visual acuity lower than 20/200
where the treating physician felt that additional therapy
would be futile due to irreversible macular damage.
Guidelines for switching treatment from bevacizumab to
ranibizumab included persistence or recurrence of either
intra-retinal, sub-retinal or sub-retinal pigment epithelium
fluid despite at least three monthly bevacizumab injec-
tions. These were based upon the clinical judgment of the
treating retina specialists for each individual patient.
Outcome was evaluated by changes in ETDRS VA and
OCT findings from baseline. OCT parameters evaluated
included central subfield thickness (CST) and central
point thickness (CPT), as well as the presence of intra-
retinal, sub-retinal, sub-retinal pigment epithelium fluid
or atrophy. Atrophy was determined by macular thin-
ning and by absence of the photoreceptor inner/outer
segment (IS/OS) junction in the central macular area.
FAs were evaluated to determine the type and location
of the lesion. Lesions were measured using the OIS
WinStation XP 5000™ (MediVision Medical Imaging,
Yokneam Elit, Israel). Genotyping was performed in 45
patients of the 67 patients included in the study. These
patients signed an IRB-approved informed consent form
Table 1 Baseline patient demographical and clinical
characteristics




Age (y) 77.48 ± 0.91
Age group
<70 y 12 (17.9)
70-80 y 27 (40.3)
>80 y 28 (41.8)


















SEM = standard error of the mean; y = years.
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cluding rs1061170 in complement Factor H (CFH),
rs1200638 in high temperature requirement A1 (HTRA1)
and rs2230199 in complement component 3 (C3) were
evaluated via sequencing as previously described [13,14,23].
Statistical analysis was performed using the SPSS
Statistics software, version 22.0 (IBM Corporation,
Somers, NY). The Paired Student t test was utilized to
analyze quantitative variables such as the VA and macu-
lar thickness across different time points compared with
the initial findings. Prevalence of categorical parameters
was compared using Fisher’s exact test, and correlations
were assessed using the Pearson test. Statistical signifi-
cance was defined as a P value of less than 0.05.
Approval for this work by the Institutional Review
Board (Helsinki Committee) of the Hadassah Medical
Center was obtained. The study was performed with in-
formed consent.
Results
Between January 2006 and January 2008, intravitreal beva-
cizumab treatment for NVAMD was initiated in 142 eyes
of 128 patients at the retina clinic of Hadassah medical
center. In 67 eyes of 61 patients, treatment was shorter
than 4 years due to death (n = 16), loss to follow-up (n =
31) or clinical judgment of stable condition or an untreat-
able state (n = 14). These 14 patients were not included as
they were not considered candidates for anti-VEGF treat-
ment since they manifested lesions predominated by either
subfoveal scaring or atrophy associated with poor visual
acuity. Baseline demographics and ocular characteristics
for 75 eyes of 67 patients treated for at least 48 months
and recruited for this study are shown in Table 1.
Initial characteristics and final outcomes are summa-
rized in Table 2. Twenty two of the eyes were previously
treated with photodynamic therapy (PDT) and were
switched to bevacizumab therapy once available; the
remaining 53 eyes were treatment naïve. Mean total le-
sion size (largest linear dimension ± SEM) measured
3184 ± 231.48 microns in the 50 eyes (66.7%) in which
this parameter was available. CNV was classified to ei-
ther classic (including predominantly classic lesions) or
occult (including minimally classic lesions) in 16 (27.1%)
and 43 (72.9%) eyes, respectively. Mean lesion size
(largest linear dimension ± SEM) measured 2330 ± 278
microns and 3417 ± 291 microns in classic and occult le-
sions, respectively. None of the patients had polypoidal
choroidal vasculopathy or retinal angiomatous prolifera-
tion. Mean follow-up time (±SD) was 60 ± 10.9 months
(range: 48–90 months), during which the average num-
ber of anti-VEGF injections (±SD) was 27 ± 12.7 per eye
or 5.4 injections per eye per year. The 25th, 50th and 75th
percentiles of cumulative injections per eye were 16, 26
(median) and 36, respectively.Baseline mean LogMAR BCVA (±SEM) was 0.66 ± 0.07
(equivalent to approximately 20/90). Mean change in
LogMAR at each time-point compared with initial BCVA
is shown in Figure 1. VA improved from baseline to a
mean of 0.5 ± 0.05 (equivalent to approximately 20/60 or
an improvement of 7.8 ETDRS letters; p = 0.044) at
24 months. From this point on, VA reduced to 0.68 ± 0.08
LogMAR (p = 0.026; compared with VA at 24 months) and
0.69 ± 0.07 LogMAR (approximately 20/95; p = 0.03; com-
pared with VA at 24 months) at 36 months and at last
follow-up, respectively. There was no significant difference
between the initial and final VA obtained after a minimum
of 4 years. Subgroup analysis of 34 eyes with an initial
LogMAR BCVA of 0.4 or less (equivalent to 20/50 or bet-
ter) demonstrated a reduction of VA from a mean initial
(LogMAR ± SEM) of 0.23 ± 0.02 to 0.40 ± 0.05 at the end
of follow-up (p = 0.0001).
Patients previously treated with PDT had an initial
BCVA (LogMAR ± SEM) of 0.83 ± 0.16 versus 0.58 ± 0.07
Table 2 Baseline and final study eye characteristics
Baseline Final
No. (%) Mean ± SEM No. (%) Mean ± SEM P value
LogMAR BCVA 0.66 ± 0.07 0.69 ± 0.07 0.600
BCVA (approximate Snellen equivalent) 20/90 20/100
20/200 or worse 13 (17.3) 15 (20)
Better than 20/200 but worse than 20/40 34 (45.3) 33 (44)
20/40 or better 28 (37.3) 27 (36)
Initial BCVA (ETDRS letters)
<45 66 (88) 66 (88)
≥45 9 (12) 9 (12)
CPT (microns) 369.8 ± 12.5 335.9 ± 25.3 0.146
CST (microns) 378.4 ± 10.1 355.4 ± 20.2 0.142
Intra-retinal fluid 47 (65.3) 23 (32) 0.038
Sub-retinal fluid 55 (76.4) 21 (29.2) 0.125
Pigment epithelial detachment 25 (34.7) 16 (22.2) 0.770
Scar 13 (18.1) 37 (51.4) 0.013
BCVA = best corrected visual acuity; CPT = central point thickness; CST = central subfield thickness; ETDRS = Early Treatment Diabetic Retinopathy Study; error of
the mean; SEM = standard error of the mean. Baseline OCT parameters were available for 72 eyes.
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viously treated with PDT (n = 22 eyes) was 0.86 ± 0.17
compared with 0.62 ± 0.07 in treatment naive eyes (n = 53
eyes; p = 0.15).
Twenty four eyes were switched to ranibizumab when
treatment failure under bevacizumab was detected by the
treating physician. These eyes received a mean (±SEM) of
28.9 ± 2.1 (range: 7–54) bevacizumab injections and a
mean (±SEM) of 7.5 ± 2.03 ranibizumab injections. VA
and thickness parameters outcome (CPT and CST) did
not differ between bevacizumab only (51 eyes) and ranibi-
zumab switched (24 eyes) eyes (data not shown).Figure 1 The mean change in LogMAR visual acuity score (±SEM) during f
baseline visual acuity is shown at each time point. BCVA = best corrected visu
respectively; ETDRS = Early Treatment Diabetic Retinopathy Study; SEM = standMean CPT and CST prior to treatment and during
therapy are shown in Figure 2. Mean baseline CPT and
CST (microns ± SEM) were 369.8 ± 12.5 and 378.4 ±
10.1, respectively. Mean CPT and CST reduced signifi-
cantly after 3 injections and remained lower than base-
line after two years of therapy. Thereafter, the thickness
increased and was similar to baseline levels at 36 months
and at last follow up, reaching a final CPT value of
335.9 ± 25.3 and CST of 355.1 ± 20.2, (p = 0.15 and p =
0.14 vs. initial thickness, respectively).
Evaluation for a possible association between VA and
retinal thickness parameters (CPT, CST) was performedollow-up (n = 75). Mean number of ETDRS letters gained or lost versus
al acuity; BEV #1, #2, #3 = first, second and third bevacizumab injections,
ard error of the mean. *p < 0.05 vs. initial; **p < 0.05 vs 2 years.
Figure 2 The mean change (±SEM) in central point thickness (CPT) and central subfield thickness (CST) measurements along the follow up
period. BEV #3 = third bevacizumab injection; OCT = optical coherence tomography; *p < 0.05 vs. initial; **p < 0.05 vs. 2 years.
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Thinned or thickened macula was defined as CST and
CPT of less or over two SD than normal average value,
respectively [24]. A direct correlation was found between
the change in BCVA and the change in CPT in a sub-
group of 34 eyes with final CPT of ≥ 275 μ (Pearson
rho = 0.41, p = 0.017). Similar findings were demonstrated
in a subgroup of 33 eyes with final CST ≥ 320 μ (Pearson
rho = 0.42, p = 0.014). We found that 25.3% of the eyes
showed CPT of less than 180 μ, which is subnormal for
the OCT system utilized [24]. VA was not associated with
such abnormally thinned macula.
Analysis of the OCT images at baseline and at the end
of follow-up revealed that prevalence of intra-retinal
fluid decreased by approximately 50% and prevalence of
sub-retinal fluid showed a trend for decreasing at final
exam compared with baseline. On the other hand, scar
tissue was almost 3-times more common at the end of
follow-up compared with baseline. Pigment epithelial de-
tachment showed similar prevalence at baseline and at
last follow up (Table 2). Eyes with atrophy at last exam
(n = 39) (absence of IS/OS and thinned macula) showed
a trend towards having a lower final VA compared with
eyes with no atrophy identified (n = 36; 0.80 ± 0.1 vs
0.56 ± 0.09 LogMAR, p = 0.09). Similar proportion of
eyes with and without atrophy at last exam were previ-
ously treated with PDT.
No other correlations were detected between VA or
thickness parameters and age, gender, number of injec-
tions, lesion characteristics according to FA, presence of
atrophy or fluid according to OCT, or any of the other
parameter which were evaluated.
The risk alleles for AMD in CFH (rs1061170), HTRA1
(rs1200638) and C3 (rs2230199) SNPs were not associ-
ated with mean VA change or initial or final VA. How-
ever, the CFH variant was associated with mean changein macular thickness parameters. Initial CPT and CST
(microns ± SEM) were 375.5 ± 19.2 and 387.4 ± 16.1 in
individuals lacking this risk allele (n = 31) and 379.4 ±
30.1 and 393.5 ± 25.9 in risk allele carriers (n = 13), re-
spectively (p = 0.91 and p = 0.84, respectively). At the
end of follow up, the CPT and CST decreased by a mean
(microns ± SEM) of 92.6 ± 26.4 and 76.8 ± 22.0 respect-
ively, in individuals lacking this risk allele. By contrast, in
carriers of the risk allele CPT and CST increased by a
mean of 79.9 ± 74.9 (p = 0.009, vs non-carriers) and 66.9 ±
70.4 (p = 0.015, vs non-carriers). Final CPT was 459.3 ±
76.8 in risk allele carriers and 284.4 ± 24.0 in non-carries
(p = 0.007) and final CST was 460.3 ± 67.5 and 312.0 ±
17.4 (p = 0.006), respectively (Table 3). The CFH risk allele
carriers and non-carriers did not differ in terms of
previous PDT treatment (23.1% versus 25.8% received
PDT treatment, respectively; p = 1.0), total number of
anti-VEGF injection (22.31 ± 4.29 versus 27.06 ± 2.03,
respectively; p = 0.3), ranibizumab treatment (38.46%
versus 29.03%, respectively; p = 0.7) or number of rani-
bizumab injections (1.62 ± 0.81 versus 1.97 ± 0.80, re-
spectively; p = 0.7).
Discussion
In this study we analyzed the long-term outcome of in-
travitreal bevacizumab therapy for NVAMD in a “real-
life” clinical setting. Approximately half of the eyes that
started therapy more than 4 years prior to the study
endpoint were still followed in our clinic and were in-
cluded in the analysis. Number of patients included and
drop-out rate from the study favorably compare with the
few reports available in the literature on this topic, such
as the SEVEN-UP study [6]. Mean visual acuity im-
proved from one through 24 months following initiation
of treatment in a magnitude similar to that obtained in
the pivotal clinical trials ANCHOR and MARINA [2,3].
Table 3 Frequency of alleles and genotypes of CFH Rs1061170, HTRA1 Rs11200638 and C3 Rs2230199 SNPs among
patients
No. (%)* Final CPT
(μ) ± SEM
P value Final CST
(μ) ± SEM
P value Change in CPT
(μ) ± SEM




TT (WT) 31 (70.5) 284.4 ± 24.0 0.007 312.0 ± 17.4 0.006 −92.6 ± 26.43 0.009 −76.8 ± 22.01 0.015
CC + TC (AT RISK) 13 (29.5) 459.3 ± 76.8 460.3 ± 67.5 79.9 ± 74.84 66.9 ± 70.38
HTRA1
GG (WT) 14 (35.9) 378.1 ± 35.7 0.57 378.1 ± 27.0 0.79 2.57 ± 35.83 0.49 −8.29 ± 32.75 0.669
AA + GA (AT RISK) 25 (64.1) 338.4 ± 47.8 362.8 ± 40.7 −47.54 ± 50.50 −36.21 ± 45.38
C3
CC (WT) 27 (60) 331.1 ± 40.6 0.95 364.2 ± 36.4 0.87 −52.04 ± 42.88 0.814 −29.81 ± 40.89 0.964
GG + GC (AT RISK) 18 (40) 326.6 ± 63.2 354.1 ± 50.7 −33.63 ± 70.62 −26.6 ± 61.255
BCVA = best corrected visual acuity; CPT = central point thickness; CST = central subfield thickness. SEM = standard error of the mean; WT = wild type. *Genotyping
results were available for 44, 39 and 45 patients (out of 45 patients tested) for CFH, HTRA1 and C3, respectively.
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follow-up of 5 years. Subgroup analysis demonstrated
substantial final visual loss in individuals who had initial
VA of 20/50 or better. Macular thickness parameters
demonstrated a similar course showing initial thinning
of the macula, followed by re-thickening after the two
year time point as well as an increase in the degree of
atrophic changes.
Limited data exist on the long-term outcome of anti-
VEGF therapy in NVAMD, particularly in a “real-life”
(versus study-controlled) setting, and previous reports
on this topic focused on ranibizumab-treated patients
[6,7,9-11]. In four years of follow-up in the ANCHOR
and MARINA extension study, the HORIZON, there
was an incremental decline of the VA gains seen during
the first 2 years of the studies. The recent SEVEN-UP
trial reported on re-examination of approximately 10%
of the original ANCHOR and MARINA cohorts. Since
enrollment to ANCHOR and MARINA trials, approxi-
mately 7 years previously, a mean loss of 8.6 letters was
reported for these patients [6]. Among the factors that
may underlie such visual loss are under- or over-
treatment, decaying medication effect (i.e. tolerance or
tachyphylaxis), and the development of macular scarring
and atrophy.
The treatment algorithm in our study, as well as in the
other long-term reports [6-11], was clinician determined.
Unlike patients included in the SEVEN-UP [6] study that
were originally treated in the ANCHOR and MARINA tri-
als, our patients were not treated initially by a fixed
monthly regimen. Furthermore, some of our patients were
previously treated with PDT and some were switched to
second-line ranibizumab therapy. The SECURE study [6]
suggested that under-treatment may be associated with
poorer visual outcome at 3 years in patients treated based
on VA [8]. In the SEVEN-UP study, better visual out-
comes were demonstrated among patients in the highestquartile of anti-VEGF treatments. That study suggested
that the low treatment frequency of 1.6 injections per year
since exit from HORIZON study, may have contributed to
the decline in mean VA [6]. However, in the HORIZON
trial, the mean number of ranibizumab injections received
by patients who had stable or improved VA at last observa-
tion (a mean of 4.2 injections) was lower than the number
received by patients with worse final VA outcome (a mean
of 4.9 injections) [9].
In the clinic setting, Pushpoth et al. reported an average
of 5.8 and 13.7 ranibizumab injections by 12 and
48 months, respectively (approximately 3.4 injections per
year). Fifty percent of the patients maintained Snellen VA
of at least 0.3 decimal over 4 years in this study [11].
Rasmussen et al., utilizing a strategy of three initial monthly
ranibizumab injections and an overall mean of 5.5 ranibizu-
mab injections per year during four years of follow-up, re-
ported of stable baseline and final VA (approximately 0.3
decimal) [10]. In our study, a similar clinician-determined
treatment algorithm was applied for bevacizumab, resulting
in a similar frequency of 5.4 injections per year.
Our results demonstrate similar deterioration from the
3rd year of treatment as seen in the HORIZON, an
open-label, multicenter study and the SEVEN-UP, a mul-
ticenter, nonintervention cohort study, and show com-
parable initial and final VA as reported from the clinic
setting studies [6,9-11]. These data suggest that in the
long-term, bevacizumab therapy results in outcomes
similar to those obtained with ranibizumab therapy. Fur-
thermore, our data suggest that the deterioration ob-
served after 2 years of therapy in the ANCHOR and
MARINA trials [2,3] cannot be entirely attributed to a
switch from a fixed monthly to a clinician determined
treatment strategy.
Tolerance or tachyphylaxis to anti-VEGF compounds
may also have a role in this poor long-term effect. Long-
term loss or reduced efficacy was reported for non-ocular
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scribed for anti-VEGF therapy in NVAMD [28], and its
prevalence in 14 to 24 months of follow-up was reported
to be between 2% to 10% [29,30]. The contribution of
tachyphylaxis and tolerance to the long-term loss of the
initial visual gain in treated NVAMD patients is still un-
known. Macular thickening accompanying visual loss from
the 3rd year of therapy and on was demonstrated in our
study. Yet, thickening was accompanied by decreased
presence of intra-retinal fluid and increased prevalence of
macular scarring. These data suggests that insufficient
VEGF blockade due to insufficient frequency of injections
or loss of their efficacy may play a role in long term VA
loss, but, that other causes of fibrosis may also at least par-
tially account for such visual loss.
Another potential major cause of visual loss in the
long-term is the development of atrophic macular
changes. Such atrophy may be caused by the primary
progression of the degeneration associated with AMD,
or secondary to the presence and regression of the CNV.
It is also possible that anti-VEGF therapy in itself results
in accelerated atrophy, as VEGF may have a role as a
neuronal survival factor and its long-term suppression
could affect retinal health. The SEVEN-UP study re-
ported that 57 of the 58 eyes (98%) examined by fundus
autofluorescence imaging had macular atrophy. The
same study demonstrated that decreased VA is associ-
ated with both increased area of macular atrophy and
presence of subfoveal macular atrophy [6]. The CATT
study reported of a higher rate of atrophy development
in the monthly anti-VEGF treated groups than in the
PRN treated groups [1]. We have estimated atrophy
based on thinning of the CPT and by absence of the
photoreceptors-IS/OS junction in the central macular
area as demonstrated on OCT imaging. We found that
macular thinning or attenuation of the IS/OS line
showed borderline association with worse long-term VA
outcome.
A correlation between the presence of the major AMD
risk allele in CFH and a worse outcome in terms of
OCT thickness parameters is another finding of the
present study. The association of this SNP with worse
outcome was inconsistently reported in other relatively
short term studies which evaluated this issue [18,31].
For example, the CATT trial and the IVAN trial con-
cluded that the major risk alleles for AMD did not pre-
dict response to anti-VEGF therapy by one year of
follow-up [18,31]. It is noteworthy that our study de-
scribes a long-term association of genotyping and out-
come while IVAN and CATT trials [18,31] describe a
shorter time outcome. In the long-term, outcome may
reflect atrophic changes or other factors that are less
relevant in the short term. In addition, a recent review
by Kanoff et al. [19], concluded based on previousreports [32-35] that presence of the high-risk C allele in
the CFH Y402H locus seems to increase both a patient’s
risk of macular degeneration and of a worse treatment
response to anti-VEGF therapy [19]. Further research is
required to explore the significance of such associations.
Several limitations of this study should be acknowl-
edged. This study includes a relatively small number of
eyes and it is retrospective, and almost 50% of cases in
which treatment was initiated were not available for the
long-term (>4 years) follow up. Some of the eyes were
previously treated with PDT and some received second-
line ranibizumab therapy. However, this cohort contains
a group of patients treated for a mean of 5 years by the
same physicians in the same facility. Similar previous stud-
ies [6,9-11] reported follow-up rate ranges from about
55% in the HORIZON study to as low as 10% in both
the SEVEN-UP study and the study by Pushpoth and
colleagues [11], underscoring the difficulty in obtaining
higher rates of follow up for such a long-term in this
elderly and highly variable patient population.
Conclusions
Our results show that three sequential monthly injections
of bevacizumab followed by a clinician-determined treat-
ment strategy led to marked VA gain which was maintained
for two years, and then subsequently gradually lost. Sub-
optimal treatment strategy, development of atrophy and
scarring, and diminishing treatment efficacy (or some com-
bination of these factors) may explain this phenomenon.
Larger prospective studies assessing long-term outcome are
required to provide insight to the mechanisms resulting in
visual deterioration in NVAMD despite a good initial re-
sponse to anti-VEGF therapy.
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